In 2021, it was proposed that cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors could be utilized with success for breast cancer, in response to metabolic reprogramming observed in melanoma following standard BRAF/MEK inhibition implicated in both therapeutic response and resistance. Here, BRAF is linked to melanoma.